Replies to post #225965 on Avid Bioservices Inc (CDMO)

[biopharm]

Dana Farber with Troy Luster and Ambit ( now actually known as Daiichi Sankyo... or the #1 biggest BP in Japan, after Takeda )

... Then again, Takeda is very close to Kyoto University and how could Kyoto flipped PS experts resist a collaboration

one day the full list will come out and I'm sure that household name will inch a bit closer to becoming a household name

[Protector]

north, I think there was also explicit mention of Dmitry I. Gabrilovich (Winstar) and some thing he was working on related to Bavi/PS targeting.

But when CEO King mentioned 24+ collaborations then there are 20 missing. Possibly Yopp/Bayer-Onyx has a place in their. Sorafenib has been VERY hard to improve on.

And collaborations could ALSO be the other way around. Just one speculation in this area could be HALO and the use of its new administration platform with Bavituximab. That would lower the cost of treatment and shorten the time needed by patients tremendously, maybe even get the Bavi part of a treatment cycle elsewhere, closer to home rather then in the main treatment centre, by means of infusions. That would improve the comfort of the patients too.

It would also take away the, ok very few but still, problems with infusion we have seen on occasion in the side-effects. At first this may not look like a big deal because it is quite exceptional and not proper to Bavi but rather to the way of administration, but for the patient it is a big deal.